Expandable versus inflatable mediastinoscopic combined with laparoscopic for radical esophagectomy

可扩张式纵隔镜与充气式纵隔镜联合腹腔镜用于根治性食管切除术

阅读:1

Abstract

BACKGROUND: A few medical centers have used the "inflatable mediastinoscope" technology in radical esophagectomy for esophageal cancer, and its safety and short-term efficacy have been limitedly verified. However, this technology has some defects. Therefore, we developed a new method for radical resection of esophageal cancer: the expanded mediastinoscopic combined with laparoscopic radical esophagectomy (EMLE). METHODS: From June 2019 to June 2022, we successfully performed 176 cases of radical resection of esophageal cancer using the new EMLE technique and recorded the baseline and perioperative patient data. We also retrieved four published clinical studies on the inflatable mediastinoscopic combined with laparoscopic radical esophagectomy (IMLE) and compared the perioperative safety differences between EMLE and IMLE. RESULTS: The EMLE group comprised 176 patients, whereas the IMLE group had 173 patients. Compared to IMLE, patients undergoing EMLE showed almost no differences in baseline characteristics but demonstrated significant advantages in terms of operative time (329.71 vs. 168.84 min) and blood loss (167.84 vs. 94.87 mL) (P < 0.001). The incidence of postoperative complications was significantly lower in the EMLE group compared to the IMLE group (P < 0.001). Specifically, the incidence of postoperative recurrent laryngeal nerve palsy was significantly lower in the EMLE group than in the IMLE group (P < 0.001). No significant differences existed in the days of the postoperative hospital stay and number of resected lymph nodes. CONCLUSION: EMLE has no disadvantages compared with IMLE. It is a radical resection of esophageal cancer with more advantages in surgical operation and blood loss control and is also worth promoting.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。